Regular trading hours are validating the massive overnight hardware numbers we tracked yesterday. Dell's blowout guidance is acting as a firewall against a deteriorating macro picture, drawing aggressive institutional accumulation even as rising bond yields and Middle East energy shocks force liquidation across the broader software and momentum tape.
Yesterday we covered Dell's blowout post-market earnings and massive $95 billion AI server backlog; today, regular trading fully absorbed that catalyst. The stock surged 15.8% to close at $492.20 on Wednesday, September 2, trading a massive 36.4 million shares and surpassing the initial $475 after-hours gap level we noted.
Why it matters
The ability of regular session volume to aggressively expand upon the overnight gap confirms heavy institutional accumulation rather than a brief exhaustion spike. Swing and day traders should track the $485 level for continuation entries or potential pullback support during the week's remaining sessions.
Snowflake Inc. (SNOW) shares jumped over 24% on Wednesday, September 2, after reporting Q2 fiscal 2027 adjusted EPS of $0.62 vs $0.45 expected on revenue of $1.55 billion (+35% Y/Y). Product revenue rose 37% to $1.49 billion, driven by adoption of its Cortex Code (9,100 accounts) and CoWork (5,800 accounts) AI tools. Management raised full-year product revenue guidance to $6.07 billion, prompting 22 brokerages to raise targets, including Wells Fargo to a Street-high $525.
Why it matters
Measurable account usage for AI tools bridges the gap between software hype and verifiable consumption growth. The sharp breakout from a multi-month base on expanding volume provides a textbook episodic pivot setup for momentum traders. Watch for institutional sponsorship to absorb any retests of the $310 breakout zone.
Hewlett Packard Enterprise (HPE) reported Q3 fiscal 2026 net revenue of $12.2 billion on Wednesday, September 2, up 34% Y/Y, with non-GAAP operating profit doubling to $2 billion. Networking revenue jumped 74.9% to $2.9 billion. Supported by an expanded order backlog, $1.8 billion in new AI orders, and an expanded collaboration with Oracle for gigawatt-scale AI infrastructure, HPE raised its FY26 and FY27 revenue, earnings, and free cash flow guidance.
Why it matters
Accelerating server backlog conversion and integration synergies from Juniper Networks position HPE for sustained earnings expansion. The stock's breakout from its multi-week consolidation pattern presents a classic long setup for swing traders, with clear trade invalidation defined below the pre-earnings consolidation low.
Broadcom Inc. (AVGO) reported fiscal Q3 adjusted EPS of $3.32 on Wednesday, September 2, beating the $3.24 consensus on revenue of $29.59 billion (+86% Y/Y). Custom AI semiconductor revenue surged 221% Y/Y to $16.7 billion, and CEO Hock Tan projected AI revenue to reach $230 billion by fiscal 2028. However, shares slipped roughly 1% after Q4 revenue guidance of $34.8 billion slightly missed the $35.03 billion market expectation.
Why it matters
Despite an incredible long-term trajectory for custom silicon, the minor Q4 guidance miss illustrates the market's high bar for semiconductor leaders. Active traders should monitor whether dip-buyers defend key moving averages or if high-multiple profit-taking extends across AI hardware supply chain peers like NVDA and AMD.
GitLab Inc. (GTLB) shares jumped 24% in pre-market and regular trading on Wednesday, September 2, after posting Q2 fiscal 2027 revenue of $286.3 million (+21% Y/Y) and non-GAAP EPS of $0.24, beating consensus views. The move was fueled by record gross bookings, a 42% surge in net ARR, and a 150% increase in deals over $500k. Full-year revenue guidance was raised to $1.129B–$1.133B.
Why it matters
GitLab's strong print disproves fears of enterprise software seats being cannibalized by AI, showing instead that integrated AI developer tools are driving expansion. The sharp gap-up over 52-week highs forces short covering and multi-quarter re-evaluations from sell-side analysts.
HUTCHMED shares surged 17% on Thursday, September 3, after signing an exclusive global development and licensing deal with GSK for its experimental KRAS-EGFR cancer therapy, HMPL-A830. HUTCHMED receives $110 million upfront and up to $1.295 billion in development, regulatory, and commercial milestones, plus tiered royalties. HUTCHMED will lead Phase I trials starting in H2 2026 before GSK takes over global development.
Why it matters
A $110 million upfront cash injection provides strong fundamental validation and non-dilutive balance sheet support for HUTCHMED's proprietary platform. The headline catalyst triggered an immediate volume-backed breakout above key moving average resistance, creating a prime candidate for momentum continuation strategies.
In a brutal reversal from the successful GENGLYCOS FDA approval and data readouts we tracked over the past two weeks, Ultragenyx Pharmaceutical (RARE) cratered 43.7% in after-hours trading to $14.95 on Wednesday, September 2. The collapse, which erased $1.14 billion in market cap, followed news that a separate pipeline asset—the Phase 3 Aspire study for apazunersen in Angelman syndrome—failed both its primary cognition and secondary endpoints, prompting immediate corporate restructuring.
Why it matters
Phase 3 clinical trial failures in key pipeline assets represent binary catalysts that trigger rapid institutional liquidation. For short-side operators and mean-reversion desks, tracking whether the flush finds support near cash-value levels or faces continued distribution is critical for managing post-gap positioning.
uniQure N.V. (QURE) submitted a Biologics License Application (BLA) and requested Priority Review from the U.S. FDA on Wednesday, September 2, for AMT-130, its gene therapy candidate for Huntington's disease. Supported by three-year Phase 1/2 data demonstrating a 75% slowing of disease progression, an FDA decision could arrive by late April or early May 2027, with peak global sales projected at $3.2 billion.
Why it matters
Securing priority review for a first-in-class treatment removes historical regulatory overhangs and creates a multi-quarter milestone runway. Active traders should watch for volume expansion as four-year follow-up data due later this month serves as the next binary catalyst.
TRX dropped 2.68% to $0.32 on Wednesday, September 2, hugging its lower Bollinger Band near the 200-period SMA on $43.4M volume. Stochastic readings hit oversold levels (4.21 %K), while the 8-hour derivatives funding rate plummeted to -0.1858%, indicating heavily crowded short positioning despite open interest declining 13% over 24 hours.
Why it matters
Severely negative funding rates combined with oversold momentum oscillators set up a mechanical short-squeeze environment. Active traders can look for a reclaim of $0.325 as invalidation for shorts, targeting a snapback rally toward $0.335 resistance.
BNB rose 1.49% to $698.51 on Thursday, September 3, approaching key technical resistance between $705.17 and $711.83. Despite bullish moving average alignment, the MACD histogram flatlined at zero while 70.8% of top and retail traders sit long (2.42:1 ratio). Open interest rose to $425.5 million with taker buy volume running 1.44x sell volume.
Why it matters
When positioning becomes overwhelmingly long while momentum indicators flatline at resistance, risk shifts toward a sharp rejection. A failure to clear $711.83 on volume sets up a short-side exhaustion trade targeting a flush back toward $686 support.
Alnylam Pharmaceuticals (ALNY) shares surged 8.5% to $267.09 on Wednesday, September 2. The catalyst was a double upgrade wave featuring Raymond James resuming coverage at Strong Buy with a $420 price target and BMO Capital initiating at Outperform with a $318 target, alongside positive ESC Congress data and a U.S. Department of Veterans Affairs contract worth up to $387.84M.
Why it matters
Tier-1 sell-side target hikes paired with major non-dilutive government contracts provide strong institutional backing to clear prior resistance zones. Day traders should look for intraday high-volume consolidation above $265 as confirmation of trend continuation.
Credo Technology Group (CRDO) stock fell from $220 to $206.63 on Tuesday, September 1, and extended losses on Wednesday after posting Q1 FY2027 revenue of $479 million (+115% Y/Y). Despite strong AI connectivity growth, a minor gross margin miss (68% vs 68.3% whisper) triggered aggressive profit-taking, dragging daily RSI to 40.9 near key support at $201.25.
Why it matters
CRDO represents a classic high-multiple flush where minor headline friction triggers severe profit-taking. Mean-reversion traders should monitor the $187–$201 support cluster for signs of seller exhaustion and volume-backed stabilization above key moving averages.
Hardware Order Backlogs Buffer High-Beta Volatility Massive multi-billion-dollar backlog expansions in hardware and networking providers like Dell and HPE are driving violent upward re-ratings, overriding broader market multiple compression.
Severe Selectivity Across Enterprise Software Earnings Software prints are seeing extreme dispersion where measurable AI consumption metrics spark parabolic breakouts, while minor margin or guidance misses trigger severe 10%+ liquidations.
Oncology Platform Monetization Ignites Biotech Catalysts Large-cap pharmaceutical licensing deals and accelerated FDA review filings are providing massive non-dilutive capital injections and immediate episodic pivots for mid-cap biotechs.
Macro Rate-Hike Fears Squeeze Extended Short Structures Surging bond yields and oil shocks are creating technical divergence, where extreme negative funding rates and oversold technicals trigger sharp short-squeeze risks.
What to Expect
2026-09-04—U.S. August Non-Farm Payrolls and Employment Situation report release.
2026-09-08—GameStop (GME) official Q2 earnings presentation.